Bisphosphonates - A word of caution

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 4 SUPPL., 2004, Pages

  Robinson, Narendran Andrew ^a,b   Yeo, J F ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Avascular necrosis; Bisphosphonates; Jaw bones; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ALVEOLAR BONE; AUSTRALIA; AVASCULAR NECROSIS; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CONFERENCE PAPER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG INDICATION; DRUG MECHANISM; HUMAN; HYPERCALCEMIA; JAW DISEASE; MULTIPLE MYELOMA; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; TOOTH FISTULA;

EID: 8144221051     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Lindsay R, Cosman F. Osteoporosis, In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2001:2226-37.
2. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
3. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
4. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003;5:65-74.
5. Rogers MJ. New insights into molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
6. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
7. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004;62:391-2.
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
9. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
10. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48:268.
11. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risks factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9.
12. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003;15:458-63.
13. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73:813-22.
14. EI-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 2003;5:5-10.
15. Meraw SJ, Reeve CM, Wollan PC. Use of alendronate in peri-implant defect regeneration. J Periodontol 1999;70:151-8.
16. Yoshinari M, Oda Y, Inoue T, Matsuzaka K, Shimono M. Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants. Biomaterials 2002;23:2879-85.